To: Lee Lichterman III who wrote (42766 ) 3/11/2000 4:14:00 PM From: Casaubon Read Replies (2) | Respond to
Many Biotechs are being slaughtered and I love many of these companies based on FA ( and II have to figure either it funding . While I would agree there is speculative hype surrounding the genome companies, it is fundamentally changing the way drugs are discovered as well as the turnaround time from the lab to the pharmacy. This translates into BIG profits. The companies which best utilize this massive compilation of data will be huge winners. Also, many more drugs are going to benefit from enhanced methods of delivery. In the past certain drugs that worked well in the lab did not translate to good performance in the clinic, due to physical limitations of absorption and other formerly difficult to control limitations. Much has been learned about drug delivery and this will have profound impacts on the viability of new drug entities. Furthermore, drugs themselves should experience fewer side effects as specificity for their respective targets improves through better understanding of disease mechanism . Again, this translates directly to the bottom line, as safer drugs will result in less litigation and better responsiveness by the patients. However, the competition is fierce and therefore, I believe, a certain critical mass is neccessary for a biotech company to hope to survive and prosper . Thus, I would avoid companies which are too small.
